Schering AG Sales BENEFIT From Betaseron Study
This article was originally published in The Pink Sheet Daily
Sales of the multiple sclerosis drug Betaseron and the oral contraceptive Yasmin grew double digits in the first nine months of the year.
You may also be interested in...
Following the acquisition of Schering AG, the move will result in the elimination of 600 positions in the U.S. and $210 mil. in annual savings.
sNDA approval makes interferon beta-1b the second biologic approved for early stage MS treatment.
The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.